Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Net Income (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Net Income data on record, last reported at -$8.3 million in Q4 2025.

  • For Q4 2025, Net Income rose 38.76% year-over-year to -$8.3 million; the TTM value through Dec 2025 reached -$19.0 million, up 74.3%, while the annual FY2025 figure was -$19.0 million, 74.3% up from the prior year.
  • Net Income reached -$8.3 million in Q4 2025 per VRCA's latest filing, down from -$308000.0 in the prior quarter.
  • Across five years, Net Income topped out at $1.5 million in Q3 2022 and bottomed at -$24.8 million in Q3 2023.
  • Average Net Income over 5 years is -$10.9 million, with a median of -$10.1 million recorded in 2022.
  • Peak YoY movement for Net Income: soared 111.79% in 2022, then crashed 1736.02% in 2023.
  • A 5-year view of Net Income shows it stood at -$9.5 million in 2021, then skyrocketed by 38.49% to -$5.9 million in 2022, then crashed by 320.06% to -$24.6 million in 2023, then skyrocketed by 45.01% to -$13.6 million in 2024, then soared by 38.76% to -$8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$8.3 million in Q4 2025, -$308000.0 in Q3 2025, and -$393000.0 in Q2 2025.